January 2021 - Press Release on new cooperation agreement

Swiss startup 4D Lifetec signs cooperation agreement with VolitionRX to validate a new compelling therapy model for early cancer detection based on liquid biopsy

To validate the promising complementarity of 4D Lifetec’s 4D Lifetest™ and the Nu.Q™ tests developed by Volition, the parties today announced the cooperation for a combined clinical trial utilizing both liquid biopsy assays on clinical samples of lung cancer patients.

Volition understands the potential of 4D Lifetest™ to screen for early cancer detection and the potential use of these combined assays as a patient enrichment technology. 4D Lifetec understands that its technology combined with the Nu.Q assays of Volition, could help establish a highly compelling business model for cancer detection based on liquid biopsy.
“Both tests have already proven their unique advantages in the early diagnosis of cancer patients in clinical trials and complement each other in an ideal way”, 4D Lifetec’s CEO Arne Faisst said. “The combination gives us the unique opportunity to validate a completely novel concept for the use of liquid biopsies in cancer diagnostics.”

Signing the cooperation agreement, both companies want to take advantage of bundling the scientific and human resources. The parties hereby express their excitement at entering into a research and development collaboration. In order to validate the complementarity of 4D Lifetec’s 4D Lifetest™ and the Nu.Q™ tests developed by Volition, the parties are collaborating in a combined clinical trial utilizing both assays on clinical samples.

To evaluate this opportunity further, the companies have already started to evaluate (based on data and published information) their technologies and exchanged clinical protocols. They now are conducting a first combined trial to evaluate the potential of this opportunity.

About 4D Lifetec AG
4D Lifetec AG is a highly innovative Swiss start up founded 2014 and led by an experienced motivated team of experts to create a footprint in the world of cancer diagnostics. The company has developed its proprietary and fully patented 4D Lifetest™ for the early detection of cancer based on a new innovative biomarker and liquid biopsy. The assay has been successfully clinically tested and shows an unprecedented potential in the early detection of cancer. First applications are just before IVD approval for the use in personalized diagnostics.

About Volition
Volition is a multi-national epigenetics company is publicly listed in the United States with research and development activities centered in Belgium, a small laboratory in California and additional offices in Texas, London and Singapore. The company is developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Contact Media & Investors
Arne-C. Faisst, PhD
Owner & CEO 4D Lifetec AG
+41 79 434 10 49
arne.faisst@4dlifetec.com
www.4dlifetec.com